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Objective: This study was undertaken to assess factors influencing short- and long-
term outcomes of surgery for rheumatic disease of the tricuspid valve.
Methods: Between 1974 and 2005, a total of 328 consecutive patients (mean age 51.3
6 13.6 years) underwent tricuspid valve surgery for rheumatic disease. There were 12
cases of isolated tricuspid lesion, 199 of triple-valve disease, 114 of tricuspid and mi-
tral valve disease, and 3 of aortic and tricuspid valve disease. Most patients (72%) had
predominantly tricuspid regurgitation. Tricuspid valve prosthetic replacement was
performed in 31 cases and valve repair in 297.
Results: In-hospital mortality was 7.6%. Late mortality was 52.1%, whereas the ex-
pected mortality of the Spanish population of the same age was 24.2%. Predictors
of in-hospital mortality were male sex, isolated tricuspid lesion, moderate aortic insuf-
ficiency, postclamping time, and tricuspid valve replacement. Mean follow-up was
8.7 years (range 1–31 years). Follow-up was 98.9% complete. Predictors of late mor-
tality were age, New York Heart Association functional class IV, postclamping time,
and mitral valve replacement. In total, 114 patients required valve reoperation, but
only 4 (3.5%) for isolated tricuspid valve dysfunction. At 30 years, actuarial survival
was 12.1% 6 4.4%, actuarial freedom from reoperation was 27.5% 6 5.8%, and
actuarial freedom from valve-related complications was 2.0% 6 1.3%.
Conclusion:Organic tricuspid valve disease associated with rheumatic mitral or aortic
lesions increases hospital and late mortality, but valve repair compared favorably with
valve replacement. Long-term results may be considered acceptable for otherwise
incurable valve disease.
I
n contrast with functional tricuspid regurgitation with annular dilatation and
structurally normal valves, organic tricuspid disease is a valvular dysfunction
caused by primary structural pathology affecting the leaflets, the subvalvular
apparatus, or both, with or without a dilated annulus. The most common cause of
organic tricuspid disease worldwide is rheumatic fever. It usually affects the mitral
valve and frequently affects the aortic valve concomitantly. Despite the dramatic
decline of acute rheumatic fever in developed countries, significant morbidity and
mortality are still associated with rheumatic heart disease in developing nations.
In our country, Spain, a large population of patients with rheumatic valve disease
have undergone diagnosis and treatment during the past 30 years, not only because
eradication of rheumatic fever occurred later than in other developed countries but
also because there has been a resurgence of the disease as a result of the influx of
immigrants from countries where rheumatic fever is prevalent.1 On the other
hand, there is a paucity of studies in the literature on the long-term results of patients
undergoing tricuspid valve surgery for organic tricuspid disease.2-4 The purpose of
this study was therefore to review our experience with patients who required
correction of tricuspid valve disease operated on between 1974 and 2005, with
the ultimate goal of assessing long-term outcomes of rheumatic tricuspid valve
surgery.
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Materials and Methods
Study Subjects
From 1974 to 2005, a total of 328 consecutive patients underwent
surgical correction at our institution for a diagnosis of valve disease
of rheumatic etiology with significant tricuspid dysfunction involving
the leaflets or the subvalvular apparatus. During the study period,
a total of 1106 patients required 1213 operations on the tricuspid valve
for tricuspid valve disease of acquired etiology (excluding active in-
fective endocarditis. The incidence of organic rheumatic tricuspid
valve disease was thus 29.7%. Operations were performed on 189 pa-
tients between 1974 and 1988 and on the remaining 139 between
1989 and 2005. There were 57 male patients and 271 female patients
(aged 51.3 6 13.6 years, range 14–81 years). Fifty-three patients
(16.2%) were in New York Heart Association (NHYA) functional
class II, 203 (61.9%) in class III, and 72 (21.9%) in class IV. A total
of 275 patients (83.8%) had atrial fibrillation. Previous cardiac oper-
ations had been performed in 88 cases (26.8%): 62 on themitral valve,
6 on the aortic valve, and 20 on both mitral and aortic valves. None of
the patients had previously undergone tricuspid valve surgery.
Almost all patients underwent preoperative investigation by
means of echocardiography in different modes according to the
year of the study, although echocardiographic findings did not con-
tribute to the indication for surgery until the appearance of 2-dimen-
sional mode. In this respect, hemodynamic studies to complement
echocardiographic examination or coronary angiographic studies
were indicated in 265 cases (80.8%). Results of hemodynamic stud-
ies are shown in Table 1.
After completion of echocardiographic and hemodynamic stud-
ies, 12 patients were found to have an isolated tricuspid lesion, 199
triple valve disease, 114 tricuspid and mitral valve disease, and 3
aortic and tricuspid valve disease. Predominant tricuspid insuffi-
ciency was present in 236 patients(72.0%), and the remaining 92
patients were considered to have predominant tricuspid stenosis.
Grades of tricuspid regurgitation were 11 in 16 patients, 21 in
55, 31 in 113, and 41 in 123. All patients had organic tricuspid le-
sions documented at surgery by the attending surgeon. Criteria for
organic tricuspid lesion included morphologic changes in the leaf-
lets or subvalvular apparatus. The most frequent findings consisted
of retraction of the free edge, thickening and appearance of calcified
foci, and some degree of fusion of the commissures.5
In 88 patients with previous valve surgery, reoperation was indi-
cated. Reasons were structural progression of rheumatic valve dis-
ease in 53 patients, structural deterioration of bioprosthesis in 30,
early failure of valve repair in 4, and dehiscence of a prosthesis in
1. The remaining 240 patients underwent primary valve surgery
for rheumatic heart disease.
Surgical Procedure
Preoperative informed consent was obtained from all patients. Op-
erations were performed through median sternotomies with cardio-
pulmonary bypass. Myocardial protection was achieved with
crystalloid cardioplegia in patients operated on until 1993 and
with antegrade or retrograde blood cardioplegia after that. The dura-The Journal of Thotion of myocardial ischemia was 66.56 34.2minutes, that of cardio-
pulmonary bypass was 107.4 6 43.6 minutes, and postclamping
time was 36.7 6 25.4 minutes. Postclamping time was defined as
the interval between the release of aortic clamps and the end of car-
diopulmonary bypass.6 Repair of the tricuspid valve was performed
on an ischemic heart in 322 patients and with the heart beating in
the remaining 6. An intra-aortic counterpulsation balloon was
implanted in 11 patients.
Decisions regarding type of surgical procedure (replacement or
repair) and type of repair (prosthetic or suture annuloplasty) were
left to the discretion of the attending surgeon. Thirty-one patients
(9.4%) underwent prosthetic tricuspid valve replacement (mechani-
cal prosthesis in 13 and bioprosthesis in 18). Repair of the tricuspid
valve was performed in 297 cases (90.5%). Types of repair were as
follows: Duran Flexible Annuloplasty Ring (Medtronic, Inc, Minne-
apolis, Minn) in 79 patients, Duran Flexible Annuloplasty Ring and
tricuspid commissurotomy in 72 patients, De Vega or segmental an-
nuloplasty7 in 108 patients, suture annuloplasty and tricuspid com-
missurotomy in 21 patients, isolated tricuspid commissurotomy in
13 patients, and other procedures in 4 patients (edge-to-edge tricus-
pid valve repair in 3). A total of 106 patients (32.3%) underwent
tricuspid commissurotomy.
Concomitant intracardiac procedures included mitral valve re-
placement in 159 patients (mechanical prosthesis in 103 and bio-
prosthesis in 56), mitral commissurotomy in 25 patients, Duran
Flexible Annuloplasty Ring in 22 patients, and Duran Flexible An-
nuloplasty Ring and mitral commissurotomy in 107 patients. Fifty
patients underwent concomitant repair of the subvalvular apparatus.
Aortic valve operations included valve replacement in 84 patients
(mechanical prosthesis in 47 and bioprosthesis in 37) and aortic
valve repair with previously described techniques8 in 33 patients.
Follow-up
The follow-up data for this study were procured in a 6-month period
(July 2006–December 2006). The patients were followed up
TABLE 1. Preoperative hemodynamic studies
Variable N Mean 6 SD Range
Pulmonary capillary
pressure (mm Hg)
216 22.4 6 8.4 6–75
Pulmonary artery systolic
pressure (mm Hg)
254 48.8 6 17.7 16–105
Left ventricular ejection
fraction (%)
239 55.2 6 10.8 22–87
Cardiac index (L $ min21 $ m22) 205 2.28 6 0.76 1.06–8.9
Aortic valve gradient (mm Hg) 61 39.9 6 27.9 1–130
Mitral valve gradient (mm Hg) 178 14.7 6 6.7 2–30
Tricuspid valve gradient (mm Hg) 35 5.3 6 2.8 1–11
Left ventricular end-diastolic
pressure (mm Hg)
123 5.8 6 3.7 2–13
Right ventricular systolic
pressure (mm Hg)
123 51.3 6 23.0 20–85
Total pulmonary vascular
resistance (dyne $ s $ cm25)
146 853 6 378 363–1231
Pulmonary alveolar resistance
(dyne $ s $ cm25)
146 259 6 205 103–528racic and Cardiovascular Surgery c Volume 136, Number 2 477
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home (n 5 185), or direct contact with their cardiologists (n 5
12). When follow-up was not possible, information on vital status
(alive or dead) and cause of death if applicable was obtained through
the Social Security database (n 5 7). Of a possible maximum fol-
low-up of 45,053 months, 44,557 months were obtained. Follow-
up was 98.9% complete, with a mean follow-up of 16.26 8.7 years
(median 7 years, range 1–31 years, 25th–75th interquartile range
2.5–13 years). The follow-up was incomplete for 4 patients who
were unavailable after 11.4, 11.5, 16.6, and 18.5 years of follow-up.
Statistical Methods
The Patient Analysis and Tracking System database, version
06.02.03 (Dendrite Clinical System, Inc, Portland, Ore) was used.
Values are expressed as mean 6 SD. The Student t test was used
for the comparison of quantitative variables. Factors influencing
in-hospital mortality (death before 30 days after surgery) were ana-
lyzed with multiple logistic regression; the results are expressed as
odds ratios. Survival curves were obtained by actuarial method.
Cox proportional hazards regression was used to study the influence
of covariates on mortality and reoperation; we present the results as
hazard ratios. Multivariate analysis was performed with the Stata In-
tercooled, release Stata 8/SE computer program (Stata Corporation,
TABLE 2. Univariate significant predictors of in-hospital
mortality
Deaths
Variable No. % P value
Sex .01
Male 271 15.8
Female 57 5.9
Valve disease .021
Isolated tricuspid valve disease 12 25.0
Polyvalvular disease 316 6.7
Aortic valve disease ,.005
Predominant aortic regurgitation 48 14.6
Predominant aortic stenosis 69 1.4
Grade of aortic regurgitation .048
1–21 74 12.1
3–41 43 2.3
Previous valve surgery ,.005
Yes 88 15.3
No 240 5.3
Tricuspid valve surgical procedure ,.005
Valve replacement 31 19.3
Valve repair 297 6.4
Aortic valve surgical procedure .029
Valve repair 33 18.2
Valve replacement 84 4.8
Use of intra-aortic counterpulsation ,.005
Yes 11 45.5
No 317 6.5
Duration of cardiopulmonary bypass ,.005
.120 min 96 15.6
#120 min 232 4.3478 The Journal of Thoracic and Cardiovascular Surgery c AugCollege Station, Tex). We compared survival in our series with an
age- and sex-matched Spanish population for which survival prob-
abilities were estimated with the Gompertz fuction.8
Results
In-Hospital Mortality
The in-hospital mortality (30-day, or within first admission)
was 7.6% (25 patients). Causes of death were cardiac in
80% of cases, bleeding in 16%, and neurologic in 4%.
Statistically significant variables in the univariate analysis
in relation to hospital mortality are shown in Table 2. On the
other hand, mean postclamping time was 62.5 6 30.9 min-
utes for deceased patients and 26.5 6 6.3 minutes for survi-
vors (P , .005).
With the multiple regression model, male sex and duration
of cardiopulmonary bypass did not reach statistical signifi-
cance. Postclamping time was the only significant risk factor
for in-hospital mortality (odds ratio 1.26 for each 10 minutes,
P , .005; Table 3). The area under the receiver operating
characteristic curve was 0.665.
Late Deaths
There were 171 late deaths among 303 perioperative survi-
vors (late mortality 52.1%). Causes of death were cardiac
in 122 patients and successive reoperations in 34 patients.
The other 15 deaths were from noncardiac causes. The
actuarial survivals were 61.8% 6 2.8% at 10 years, 38.4%
6 3.1% at 20 years, and 12.1%6 4.4% at 30 years (Figure 1).
We estimated survivorship in a cohort of Spanish people of
the same age and sex distribution by assuming a Gompertz
model of mortality. Overall survivals were 96.3%, 89.0%,
and 75.8% at 10, 20, and 30 years, respectively (Figure 1).
In the univariate analysis, operation before 1989 and
NYHA functional class IV were significant predictors of
late death. Mortality was 65.7% among patients who
TABLE 3. Predictors of mortality in multivariate analysis
Variable
Odds or
hazard ratio
95%
Confidence
interval
P
value
Hospital mortality (odds ratio)
Male sex 1.91 0.79–4.66 NS
Cardiopulmonary bypass .120 min 1.80 0.83–3.93 NS
Postclamping time (each 10 min) 1.26 1.12–1.43 ,.005
Late mortality (hazard ratio)
Age (each 1 y) 1.04 1.02–1.06 ,.005
NYHA functional class IV 1.57 0.99–2.49 .056
Severe postoperative complications 1.43 0.92–2.21 .111
Mitral valve replacement vs repair 1.50 0.95–2.37 .080
Postclamping time (each 10 min) 1.11 1.01–1.23 .025
Reoperation (hazard ratio)
Age .40 y 0.68 0.46–1.01 .058
NYHA, New York Heart Association.ust 2008
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CDunderwent operation before 1989 and 32% among those who
underwent operation after 1989 (P , .005). Mortality was
63.3% among patients in NYHA class IV and 46.1% among
patients in NYHA class II or III (P 5 .017). On the other
hand, patients undergoing tricuspid prosthetic implantation
showed similar mortality to those undergoing tricuspid valve
repair (52.2% vs 51.4%). Mortality was higher for mitral bio-
prosthesis implantation (68.7%) than for mechanical mitral
vale replacement (34.0%), but the cause of this higher mortal-
ity was related to cardiac reasons rather than to successive re-
operations for structural deterioration of the bioprosthesis.
In the multivariate analysis, age (hazard ratio 1.04 for each
year), NYHA class IV (hazard ratio 1.57), postclamping time
(hazard ratio 1.11 for each 10 minutes), and mitral valve re-
placement compared with mitral valve repair (hazard ratio
1.50) were predictive factors for late death (Table 3).
Reoperations
Of the 303 patients who survived the operation, 114 (37.6%)
required reoperation because of isolated mitral dysfunction (n
5 23), isolated tricuspid dysfunction (n 5 4), isolated aortic
dysfunction (n 5 4), mitral and aortic dysfunction (n 5 12),
mitral and tricuspid dysfunction (n5 36), aortic and tricuspid
dysfunction (n5 2), andmitral, aortic, and tricuspid dysfunc-
tion (n 5 33). Indications for surgery included structural de-
terioration of mitral, tricuspid, or aortic bioprosthesis in 37
patients, progression of rheumatic valve disease in 49, pros-
thetic endocarditis in 6, dehiscence of a prosthesis in 12, and
early failure of valve repair in 10. There were 27 deaths
among 114 patients undergoing reoperation (mortality
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Figure 1. Actuarial survival curve for all causes of death (thin
solid line) with 95% confidence interval (dashed lines). Thick
solid line represents expected survival curve for cohort of Spanish
populationwith same age and sex distribution. Number of patients
at risk are displayed every 5 years.The Journal of Thor23.7%). Twenty-four patients required a second reoperation,
and 7 required a third reoperation.
In the univariate analysis, need for reoperation was signif-
icantly higher among patients younger than 40 years
(60.98%) than among patients older than 40 years (27.3%;
P5 .005), among patients with sinus rhythm (53.3%) preop-
eratively than among patients with atrial fibrillation (34.8%;
P 5 .019), among patients with mitral valve repair (45.1%)
than among patients with mitral valve replacement (32.4%;
P 5 .027), among patients with mitral valve bioprostheses
(69.4%) than among patients with mechanical prostheses
(14.1%; P, .005), among patients with aortic valve biopros-
theses (62.8%) than among patients with mechanical prosthe-
ses (15.6%; P , .005), and among patients with tricuspid
valve stenosis (50.6%) than among patients with nonstenotic
tricuspid valve lesions (28.6%; P, .005). In the multivariate
analysis, younger patients had higher risk for reoperation
(hazard ratio 0.88 for each 10 years of age); age older than
40 years was a significant protective factor for reoperation
(hazard ratio 0.68). The actuarial curve values for freedom
from reoperation were 68.7% 6 3.1% at 10 years, 40.4%
6 4.2% at 20 years, and 27.5%6 5.8% at 30 years (Figure 2).
During the follow-up, 10 patients had infective endocardi-
tis; 4 were treated medically and 6 required reoperation.
Thromboembolic episodes were recorded in 66 patients (cen-
tral without sequelae in 28, central with sequelae in 26, and
peripheral in 12). Major bleeding episodes related to antico-
agulation were recorded in 44 patients. The actuarial curve
values for freedom from valve-related complications were
42.0% 6 2.9% at 10 years, 18.7% 6 2.6% at 20 years, and
2.0% 6 4.3% at 30 years.
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Figure 2. Actuarial curve for freedom from reoperation (thick solid
line) with 95% confidence interval (dashed lines). Number of
patients at risk are displayed every 5 years.acic and Cardiovascular Surgery c Volume 136, Number 2 479
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in NYHA functional class I or II, 23 (18%) were in class III,
and 1 (0.8%) was in class IV.
Discussion
This study presents a 30-year experience at a university cen-
ter with a homogeneous clinical series of consecutive patients
with rheumatic heart disease involving the tricuspid valve.
Long-term results of tricuspid valve lesions of rheumatic
origin were published in the literature 10 to 20 years ago,9
coinciding with eradication of rheumatic fever in most indus-
trialized countries.10,11 In our country, the eradication of
rheumatic fever occurred later, and for this reason rheumatic
tricuspid valve lesions have been seen frequently in the recent
past. On the other hand, follow-up of patients even 30 years
after cardiac surgery is relatively easy to obtain,12,13 because
the Spanish health care system provides full coverage for
100% of the population. In this respect, our findings add ev-
idence of the natural history of surgical treatment of rheu-
matic heart disease, in particular involving the tricuspid
valve. Recently, McCarthy and colleagues14 reported the
long-term results of tricuspid valve repair in 790 patients
with functional tricuspid valve dysfunction.
In our overall experience (1974–2005) with 328 consecu-
tive patients with significant tricuspid dysfunction in the con-
text of polyvalvular rheumatic disease, in-hospital mortality
was relatively low (7.6%), although slightly greater than in
patients with isolated mitral valve surgery.15 Previous valve
surgery, duration of cardiopulmonary bypass longer than
120 minutes, and tricuspid valve replacement rather than
repair were significant predictors of in-hospital mortality.
Tricuspid valve replacement is associated with high in-hospi-
tal mortality (19.3%), reaching 37% in our overall experi-
ence.16 These results may be explained by taking into
account that only 9% of patients with tricuspid valve disease
need valve replacement operations, compared with 91%
treated with valve repair procedure.
On the other hand, in-hospital mortality was associated
with clinical and surgical characteristics of the aortic lesion.
Patients with moderate aortic regurgitation (21–31) had
a significantly higher mortality (12.1%) than did patients
with severe aortic dysfunction (41, 5.3%), which may be
explained by the use of repair procedures in patients with
moderate aortic dysfunction during the initial period of our
experience (1974–1988). In a previous study, long-term
functional results of reparative procedures for nonsevere
aortic valve disease in patients with predominant rheumatic
mitral valve disease have been inadequate at 22 years of
follow-up.8 Conservative operations for rheumatic aortic
valve disease are associated with poorer outcome than are
conservative operations for rheumatic disease of the mitral
valve.8,13,17
In agreement with a previous study of long-term perfor-
mance of the Top Hat valve (CarboMedics Inc, Austin,480 The Journal of Thoracic and Cardiovascular Surgery c AuTex) in a modern series of patients undergoing aortic valve
replacement,6 postclamping time was a significant predictor
of in-hospital mortality in both univariate and multivariate
analyses (the risk for a fatal outcome increased by 1.26 for
each 10 minutes of postclamping time). Prolonged post-
clamping time indicates that some intraoperative problems
had occurred, leaving little margin for therapeutic maneuver,
as factors affecting postclamping time are hardly modifiable.
It is reasonable to consider that severe intraoperative compli-
cations, such as perioperative myocardial infarction or ven-
tricular dysfunction, would be associated with a higher
postoperative morbidity (respiratory distress, renal failure,
and other) that could influence long-term results. We there-
fore suggest that postclamping time represents an omnibus
risk factor that acts as a surrogate for a number of complica-
tions in the perioperative period.
The area under the receiving operating characteristic
curve for the in-hospital mortality model was 0.665, reflect-
ing relatively low discrimination. It is possible that other
risk factors for in-hospital death remain unidentified in this
study.
In this series with complete follow-up in 98.9% of cases,
late mortality during the 30-year study period was high
(52.1%). As might be expected for a group of young patients
(mean age 51 years) with chronic rheumatic heart disease, the
main cause of death was cardiac, related to the need for reop-
eration or terminal heart failure. The actuarial survival at 30
years was 12%. This figure dramatically contrasts with the
75.8% survivorship at 30 years of a cohort of Spanish people
of the same age and sex distribution, although it should be
noted that survivorship of Spanish women is the second high-
est worldwide after Japan, and women accounted for 82.6%
of our series.
Other predictive factors for late death included such clas-
sic risk factors as age, NYHA class IV, and mitral valve re-
placement as opposed to repair. In line with the natural
aging process, patients who underwent operation before
1989 showed a higher mortality than did those operated on
more recently.
Surgery for rheumatic valve lesions is palliative. In this
study, the actuarial curve value for freedom from reoperation
was 27.5% at 30 years. There are two remarkable findings:
high mortality associated with reoperation (23.7%), which
is consistent with other studies,18 and reappearance of left-
sided valve dysfunction as the main reason for reoperation
(95.6% of cases). Isolated tricuspid valve dysfunction was
the cause of reoperation in only 4 of 114 cases (3.5%). On
the other hand, patients with stenosis of the tricuspid valve
showed a greater probability of reoperation than did those
with tricuspid regurgitation.
Results of tricuspid valve repair surgery for organic dis-
ease are less favorable than are repair procedures for func-
tional tricuspid disease. Some authors advocate modern
repair techniques, such as edge-to-edge valvuloplasty, asgust 2008
Bernal et al Surgery for Acquired Cardiovascular Diseaseeffective adjuvants to annuloplasty or commissurotomy.19 In
our experience, the Alfieri procedure was used in 3 patients,
with acceptable functional results. Tricuspid valve replace-
ment in advanced rheumatic heart disease is a high-risk pro-
cedure. Other authors have reported a very high mortality rate
of 26%, with a survival of 37% at 10 years.2 Preliminary data
have shown that the mitral homograft could be an alternative
to replacement of the tricuspid valve.20
Although this clinical study presents a 30-year experience,
from 1974 to 2005, in the course of which important clinical,
diagnostic, and surgical advances took place, short-term,
midterm, and-long-term results are in accordance with re-
cently published data. The mortality associated with tricuspid
valve repair surgery is slightly higher than that associated
with isolated mitral valve surgery, and according to different
authors varies from 8% to 13%.3,4 Results at 10 years showed
survivals of 59% and 61%,3,4 coinciding amazingly well with
our actuarial survival of 61.8% at 10 years. The limited
experience with rheumatic tricuspid valve surgery recently
published in the literature2,11,21 is consistent with our find-
ings of poor outcomes after prosthetic tricuspid valve
replacement.
In conclusion, rheumatic tricuspid valve disease aggra-
vates the prognosis of rheumatic heart disease, particularly
in the long term. Clinical results are more favorable after tri-
cuspid valve repair than after prosthetic replacement of the
tricuspid valve.
We thank Marta Pulido, MD, for editing the manuscript and for
editorial assistance.
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